Floatz logo

[ 18f]3f4ap

Radiculopathy

Yale UniversityradiopharmaceuticalPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Radiculopathy cohort.

Asset / SponsorPhaseRating
Kenacort
University of Miami
Phase 4BBB
Lidocaine
Sheba Medical Center
Phase 4BBB
sp-102
Semnur Pharmaceuticals, Inc.
Phase 3BB
Dexasone
Semnur Pharmaceuticals, Inc.
Phase 4BB
Celestone
Sheba Medical Center
Phase 4BB

View all 35 →

Same molecule, other indications

[ 18f]3f4ap is also rated in:

traumatic brain injuryDormant
CC
Indicative · Phase 1
43 / 100
View asset →
demyelinating diseaseActive
CC
Indicative · Phase 1
43 / 100
View asset →
spinal cord injuryActive
CC
Indicative · Phase 1
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →